EcoDrugPlus

Nuclear Receptor Subfamily 3, Group C, Member 1 (Glucocorticoid Receptor)

Ensembl ID : ENSOTSG00005000998
Gene Symbol: NR3C1
1 Cross references
200 Possible Orthologues:

Nuclear Receptor Subfamily 3, Group C, Member 2

Ensembl ID : ENSOTSG00005013793
Gene Symbol: NR3C2
1 Cross references
203 Possible Orthologues:

Nuclear Receptor Subfamily 3, Group C, Member 2

Ensembl ID : ENSOTSG00005034800
Gene Symbol: NR3C2
1 Cross references
207 Possible Orthologues:

Nucleotide Binding Oligomerization Domain Containing 2

Ensembl ID : ENSOTSG00005020112
Gene Symbol: NOD2
3 Cross references
166 Possible Orthologues:

Opiate Receptor-Like 1

Ensembl ID : ENSOTSG00005012589
Gene Symbol: OPRL1
1 Cross references
185 Possible Orthologues:

Opiate Receptor-Like 1

Ensembl ID : ENSOTSG00005039988
Gene Symbol: OPRL1
1 Cross references
184 Possible Orthologues:

Opioid Receptor Delta 1

Ensembl ID : ENSOTSG00005036345
Gene Symbol: OPRD1
1 Cross references
185 Possible Orthologues:

Opioid Receptor Delta 1

Ensembl ID : ENSOTSG00005038207
Gene Symbol: OPRD1
3 Cross references
185 Possible Orthologues:

Opioid Receptor Delta 1

Ensembl ID : ENSOTSG00005043943
Gene Symbol: OPRD1
3 Cross references
185 Possible Orthologues:

Opioid Receptor Kappa 1

Ensembl ID : ENSOTSG00005022944
Gene Symbol: OPRK1
1 Cross references
192 Possible Orthologues:

Opioid Receptor Kappa 1

Ensembl ID : ENSOTSG00005020428
Gene Symbol: OPRK1
1 Cross references
192 Possible Orthologues:

Opioid Receptor, Kappa 1

Ensembl ID : ENSOTSG00005046127
Gene Symbol: OPRK1
1 Cross references
197 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).